US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
アメリカ
USOTC
Hypebeast Ltd (PK) (HYPPF) 銘柄情報

Hypebeast Ltd (PK) (HYPPF)

0.0189

0.00

(0.00%)

終了 7月6日 5:00AM

Hypebeast Ltd (PK) (HYPPF) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

0.0189

( - )

買値

0.0001

売値

295,200.06

出来高

-

0.00 日の範囲 0.00

0.005 52 週間の範囲 0.0498

時価総額

前日終値

0.0189

始値

-

時刻

最終取引時間

財務取引量

-

VWAP

-

平均取引量 (3 か月)

US$ 622,291

発行済株式数

2,013,330,431

配当利回り

0 (2.17%)

PER

18.71

1 株当たり利益 (EPS)

0.01

歳入

582.16M

純利益

17.56M

Hypebeast Limited, through its subsidiaries, operates as a digital media company in Hong Kong, the United States, the People’s Republic of China, and internationally. It operates through Media, and E-commerce and Retail segments. The company produces and distributes youth focused digital content, wh... Hypebeast Limited, through its subsidiaries, operates as a digital media company in Hong Kong, the United States, the People’s Republic of China, and internationally. It operates through Media, and E-commerce and Retail segments. The company produces and distributes youth focused digital content, which includes fashion, lifestyle, technology, art and entertainment, culture, and music to its visitors and followers, as well as offers agency services. It also engages in online and offline retail of third-party branded clothing, shoes, accessories, and lifestyle goods on its e-commerce platform; provision of advertising spaces and services for creative agency projects; and publication of magazines. The company was founded in 2005 and is headquartered in Tsuen Wan, Hong Kong. Hypebeast Limited is a subsidiary of CORE Capital Group Limited. 詳細を表示

セクター

Media

業界

Interactive Multi-media

ウェブサイト

www.hypebeast.com

本社

Tsuen Wan, Hong Kong

設立

2026

Hypebeast Ltd (PK) is listed in the Media sector of the その他OTC with ticker HYPPF. The last closing price for Hypebeast (PK) was US$0.02. Over the last year, Hypebeast (PK) shares have traded in a share price range of US$ 0.005 to US$ 0.0498.

Hypebeast (PK) currently has 2,013,330,431 shares in issue. The market capitalisation of Hypebeast (PK) is US$38.05 million. Hypebeast (PK) has a price to earnings ratio (PE ratio) of 18.71.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0.0189	0.0189	0.0189	500	0.0189	CS
12	0.0139	278	0.005	0.0189	0.005	125	0.0189	CS
26	0.0139	278	0.005	0.0189	0.005	1938	0.00544839	CS
52	-0.018325	-49.2276695769	0.037225	0.0498	0.005	1680	0.01803338	CS
156	0.0039	26	0.015	0.0647	0.003	10151	0.03143674	CS
260	-0.1391	-88.0379746835	0.158	0.158	0.003	24618	0.10880103	CS

HYPPF - Frequently Asked Questions (FAQ)

What is the current Hypebeast Ltd (PK) share price?

The current share price of Hypebeast Ltd (PK) is US$ 0.0189

How many Hypebeast Ltd (PK) shares are in issue?

Hypebeast Ltd (PK) has 2,013,330,431 shares in issue

What is the market cap of Hypebeast Ltd (PK)?

The market capitalisation of Hypebeast Ltd (PK) is USD 38.05M

What is the 1 year trading range for Hypebeast Ltd (PK) share price?

Hypebeast Ltd (PK) has traded in the range of US$ 0.005 to US$ 0.0498 during the past year

What is the PE ratio of Hypebeast Ltd (PK)?

The price to earnings ratio of Hypebeast Ltd (PK) is 18.71

What is the cash to sales ratio of Hypebeast Ltd (PK)?

The cash to sales ratio of Hypebeast Ltd (PK) is 0.56

What is the registered address of Hypebeast Ltd (PK)?

The registered address for Hypebeast Ltd (PK) is Cable TV Tower, Tsuen Wan, New Territories

What is the Hypebeast Ltd (PK) website address?

The website address for Hypebeast Ltd (PK) is www.hypebeast.com

Which industry sector does Hypebeast Ltd (PK) operate in?

Hypebeast Ltd (PK) operates in the Interactive Multi-Media sector

manibiotech

manibiotech 5分前

It is on the home page

https://nwbio.com/

mick

and fowler 3rd run beat me

BigBadWolf

BigBadWolf 5分前

Obviously some haven't read or lack the knowledge to understand said. https://www.sec.gov/Archives/edgar/data/96664/000107997326000298/rnwf-form10.htm
So again I will provide the link for all the investing public to read or re-read😏
https://www.otcmarkets.com/stock/AMFN/discl

mick

another second / mick / fowler nicked me

DrivenByPain

DrivenByPain 7分前

$SNTX! Every Week A New High IMO! 🤑

1kgwxman

1kgwxman 10分前

Boilerplate language is common with stocks from the otcbb all the way up to the NYSE.
Nothing sinister.
Nothing illegal.
If you want safe, buy a bond or mutual fund.
Penny stocks carry more risk than other investments.
Yawn...I'm still buying more AMFN this week.

stressfreeliving

stressfreeliving 18分前

$COSM will be 🔥 this week.

Golden Cross

Golden Cross 18分前

Bid sitters will end up chasing soon...

TightCoil

TightCoil 19分前

Spanking? Looks to me like
YOU need one - Load Up

stressfreeliving

stressfreeliving 19分前

againstallodds

againstallodds 20分前

Typo on PDIV. Should be 5th

TightCoil

TightCoil 25分前

Sounds like you is
doin' some serious
speculating

WhenLambo

WhenLambo 26分前

I see I don’t really follow soccer as much as I do basketball and baseball. I went back to read the verbiage from FIFA about the VOD content, and they do say that the replay material would be available after the concert series is finished (ends on July 19th finale halftime show)

Achilles deFlandres

Achilles deFlandres 26分前

No child left behind? 79.9% is very close to 5:1.

pos_stock_hoarder

pos_stock_hoarder 28分前

Puddles Pity Party - WAR PIGS (Black Sabbath Cover)

https://youtu.be/WT8t3i8CkMQ

improving

improving 28分前

“They can’t raise any money for trials with that type of market cap.” (Ihub Post# 832596)

Here’s an international pharma market research group that seems to think otherwise:
“By 2036, among all the emerging therapies in the High-Grade Glioma Market Size, the highest revenue is

Twiggs333

Twiggs333 29分前

FDA Tracker flagged Definium’s Voyage Phase 3 GAD trial as having a July 1, 2026 primary completion date for NCT06741228. FDA Tracker notes primary completion dates can be a useful signal that trial results coming soon.

https://www.fdatracker.com/2026/07/phase-3-clinical-trials-with-p

Twiggs333

Twiggs333 29分前

FDA Tracker flagged Definium’s Voyage Phase 3 GAD trial as having a July 1, 2026 primary completion date for NCT06741228. FDA Tracker notes primary completion dates can be a useful signal that trial results coming soon.

https://www.fdatracker.com/2026/07/phase-3-clinical-trials-with-p

haha11

haha11 31分前

$SPY.....30....DLY...Look like SPY BL OPINION

30...Look for H...Line above R at top and H...Line S...under ...
https://stockcharts.com/sc3/ui/?s=SPY&p=30&yr=0&mn=0&dy=4&id=p14733199578&a=234724271
DLY..
https://stockcharts.com/sc3/ui/?s=SPY&p=D&yr=0&mn=1

boobb2

boobb2 33分前

What I see in the last year is crypto losing half it's value ( we have no idea what crypto tokens MCIC has) at one time it was suppose to be worth 5 million dollars....plus we had a very large % of Dilution in the stock............with nothing to show for it so far...evidently the billions of dollar

along4zride

along4zride 34分前

Yes . Yes this is true. Unfortunately this will not work out the way tin cup panhandler with $.42 cent shares in cup is hoping. Brand spanking new IPO shares will not be traded one for one with existing (FNMA) shares . Let’s say IPO shares are $50 each and at that time (FNMA ) shares are $5 panhandl

Make It Jake

Make It Jake 37分前

Current AIM-CASH weekly values – Large- and mega-caps decreased, mid-caps were unchanged, and small-caps increased.

Large- and mega-cap stocks : 61.1%
Below average returns and win rates in the shorter holding periods and average or above in the longer ones. Ch

nowwhat2

nowwhat2 38分前

SUNDAY and right AT the 200 week

https://investorshub.advfn.com/uimage/uploads/2026/7/5/iwuvgBTC_JULY_5_10y_2pm_snip_RIGHT_AT.jpg

https://investorshub.advfn.com/uimage/uploads/2026/7/5/lzhpibtc_july_5_9d_2pm_MAFIA_200_SNIP_LOL.jpg

ZeroGravitas

ZeroGravitas 42分前

Thanks Clive. You've posted about doing this with 3X funds before but i completely forgot about it. Thanks for bringing it back to my attention again.

ZG

DJ Emerging Markets Meta...

Midsouth Bancorp

Principal Spectrum Prefe...

Phathom Pharmaceuticals

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。